SARMs
ACP-105
ACP-105 is a non-steroidal SARM studied in lean mass and bone-density research. Below, we compare vendors currently stocking research-grade ACP-105 — not just a single sales page.
ACP-105 is a non-steroidal SARM studied in lean mass and bone-density research. Below, we compare vendors currently stocking research-grade ACP-105 — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 Next ChemBest Value |
$71.95 (20mg/mL liquid solution, 50mL) | Third-party COA | Auto-applied | Buy Here → |
 Chemyo |
$79.99 (10mg/ml solution) | Third-party COA | Buy Here → |
ACP-105 is a nonsteroidal selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals, one of the lesser-studied compounds in the SARM class with a comparatively small published research footprint.
Research-grade ACP-105 is typically supplied as capsules or a liquid solution, commonly at 5mg to 10mg per dose, intended for laboratory research use only.
Like other SARMs, ACP-105 is studied for selective androgen receptor activation intended to produce anabolic effects in muscle and bone tissue with reduced activity in other androgen-sensitive tissue, though the specific preclinical dataset supporting this for ACP-105 is considerably smaller than for better-studied SARMs.
ACP-105 originates from the same Ligand Pharmaceuticals SARM discovery program associated with LGD-4033, but has a much more limited independently published research record, with most available information sourced from patent filings rather than peer-reviewed trial data.
Researchers examining ACP-105 typically do so in the context of comparing structure-activity relationships across the broader SARM class rather than as a standalone, independently well-characterized compound.
Because independently published research on ACP-105 is limited primarily to patent-level data, its human safety profile is essentially uncharacterized. It has never been evaluated in human clinical trials, is not FDA-approved, and no meaningful human safety data exists.
No dosage of any kind has been clinically validated for ACP-105 in humans. Any figures found outside patent-level preclinical data should be treated as unverified.
Compound X does not sell ACP-105 directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
Limited available ACP-105 information is found in Ligand Pharmaceuticals patent filings and general SARM-class review literature indexed on PubMed under "selective androgen receptor modulator ACP-105."
New guides, vendor comparisons and compound breakdowns every week.